fda import alert semaglutide green list tirzepatide FDA introduces "Green List" for GLP-1 drug ingredients The FDA "Green List" -

Each vial contains 5mg of TB-500 (Thymosin Beta-4 analogue) and 5mg of BPC-157 (Body Protection Compound-157), co-lyophilised into a single vial for research convenience

Its ultra-micronized, meaning that its broken into very, very fine particles to deliver maximum absorption into the body and contribute to lean muscle support, weight management and fitness support

Where semaglutide activates only GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

The most common side effects are gastrointestinal like nausea, vomiting, and diarrhea

Eleven out of 15 studies reported changes in HbA1c, with the most significant reductions observed when compared to placebo